Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/273742 
Erscheinungsjahr: 
2022
Quellenangabe: 
[Editor:] Jain, Geetika et al. [Title:] Technological Innovations for Sustainability and Business Growth [ISBN:] 9781522599401 [Series:] Practice, Progress, and Proficiency in Sustainability [Publisher:] IGI Global [Place:] Hershey, PA [Year:] 2022 [Pages:] 91-104
Verlag: 
IGI Global
Zusammenfassung: 
Pharmaceutical firms have a noteworthy contribution in SDGs (Sustainable development goals). Their unceasing innovation of low-cost medicines and discovery of lifesaving drugs can assist in achieving the SDG 3 (good health and well-being). Having gone through the M&A scenario in the global pharmaceutical industry and the amount disbursed on R&D, the authors tried to find answers to a few important questions to understand whether these activities are in line to achieve global goals i.e. first, does Merger and Acquisition M&A in pharmaceutical sector increase innovations? Second, how can companies fully utilize M&A activities to increase innovation in the pharmaceutical sector? Third, is there any association between R&D expenditures and innovation outcome? We theoretically analyze and consolidate academic research on how M&A activities support innovation in the pharmaceutical industry. The present chapter also tried to unveil the association between R&D expenditures and the firm innovation as measured by the number of patent applications by selected Indian pharmaceutical firms.
Persistent Identifier der Erstveröffentlichung: 
Dokumentart: 
Book Part
Dokumentversion: 
Published Version
Erscheint in der Sammlung:

Datei(en):





Publikationen in EconStor sind urheberrechtlich geschützt.